FUM Futura Medical plc

Incanthera PLC (AQSE:INC) has signed its first recurring revenue deal, supplying skincare creams to LED device maker iSmart Developments. It's a big step as the company shifts away from direct-to-consumer sales. Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF) has struck a deal with Mexico's largest private hospital network to pilot its Steriwave infection treatment. Trials showed a 40% drop in post-surgical infections. Rainbow Rare Earths Ltd (LSE:RBW, OTC:RBWRF, FRA:RR1) has moved its Uberaba project in Brazil into pre-feasibility work with Mosaic. Early economics already show a $916 million net present value. Tertiary Minerals PLC (AIM:TYM, OTC:TTIRF, FRA:TMU) says new drilling at Mushima North project in Zambia has extended mineralisation beyond its existing target. Most of the latest holes ended while still in mineralisation. Strategic Minerals PLC (AIM:SML) has secured two more years of access to its Cobre magnetite stockpile in New Mexico. That extends an important cash flow source through to 2031. Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has upsized its retail share offer after strong investor demand. The wider fundraise has now conditionally raised around £1.8 million. Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.

Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the consumer healthcare company behind the erectile dysfunction gel Eroxon, has increased the size of its retail share offer after strong demand from investors. The retail offer closed on Friday, having attracted applications well beyond the...

Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX), the sexual health group behind the Eroxon erectile dysfunction gel, has begun a formal process that could see the sale of the business, or its assets. The move comes alongside a placing and subscription to raise approximately £1.6 million,...

Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) has passed a series of operational milestones across its sexual health portfolio as it repositions for growth following a strategic review. The AIM-listed group behind Eroxon, the over-the-counter erectile dysfunction gel, appointed Market...